A class of blockbuster diabetes and weight loss drugs may offer an unexpected shield against cancer. New research presented at a major oncology conference has found a strong association between GLP-1 medications and a significantly reduced risk of developing more than a dozen different cancers, a finding that could reshape the future of cancer prevention.
The study, led by a team at a Texas academic health center, analyzed de-identified patient data from a global health database. The researchers identified a consistent reduction in cancer risk among patients taking GLP-1 drugs compared to those who did not. The protective signal was seen across nearly 13 obesity-related cancers, including liver, pancreatic, gastric, and bile duct cancers, as well as breast cancer and acute myeloid leukemia. Obesity is a well-established driver of malignancy, and these findings suggest the drugs may counteract that risk.
“What we’re seeing is a cancer risk reduction signal across almost 13 different cancers,” the lead researcher said. “If this hypothesis is validated through upcoming clinical trials, we could be talking about a medication that could possibly reduce somebody’s risk of getting 13 different cancers. This could literally forever change the practice of medicine.” The team was among the first in the world to identify this broad association between GLP-1 use and reduced cancer risk.
From Discovery to Global Impact
The research earned the lead investigator the prestigious Healio NextGen Disruptor Award at the American Society of Clinical Oncology annual meeting. The award recognizes early-career researchers whose work has the potential to transform patient care. The investigator, originally from the Bahamas, now aims to translate these findings into better health outcomes for patients in South Texas and around the world.
While the results are observational and not yet proven in clinical trials, they open the door to a revolutionary possibility. If future studies confirm that GLP-1 drugs can lower the risk of multiple cancers, the medications could become a cornerstone of preventive medicine. The team’s next step is to help design and support the clinical trials needed to validate the hypothesis, bringing hope to millions of patients who face elevated cancer risk due to obesity.